Cross-border merger of BioAlliance Pharma and Topotarget legally effective as of July 22, 2014

        Print
| Source: Topotarget
multilang-release

Final calendar for trading on both Euronext and NASDAQ OMX to be available soon

To NASDAQ OMX Copenhagen A/S
Announcement no. 18-14 / Copenhagen, July 23, 2014

Paris (France), Copenhagen (Denmark), July 23, 2014 BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, and Topotarget A/S (NASDAQ OMX Copenhagen – TOPO), announce that the cross-border merger between the two companies is legally effective as of July 22, 2014, creating Onxeo, dedicated to orphan oncology diseases. 

BioAlliance Pharma, as the absorbing entity, will remain admitted to trading on Euronext Paris and will file for approval on the secondary trading and official listing on NASDAQ OMX Copenhagen. The final corresponding calendar will be announced shortly. The company will then operate under the name of Onxeo.

Onxeo will aim at becoming a global leader on the fast-growing market of orphan oncology drugs. It will hold a complementary portfolio of advanced programs targeting severe pathologies for which there is an unmet medical need. Onxeo will offer reinforced market attractiveness, notably towards specialized international investors, through a more important critical mass, a European scale and a portfolio of high added value products.

 

 

For further information, please contact:

BioAlliance Pharma:

Judith Greciet, Chief Executive Officer +33 1 45 58 76 00
Caroline Carmagnol - AlizéeRP +33 6 64 18 99 59 

Topotarget:

Bo Jesper Hansen, Executive Chairman of the Board +45 26 12 83 84
Anders Vadsholt, Chief Executive Officer +45 28 98 90 55
Michael Steen-Knudsen – Impact Communications
+45 25 17 18 15


About BioAlliance Pharma
Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases. Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA. BioAlliance Pharma has developed an advanced product portfolio:

Orphan Oncology products:
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on-going
Validive® (Clonidine Lauriad®) (mucositis): Phase II on-going
AMEP®/Synfoldin (invasive melanoma): Clinical and preclinical phase

For more information, visit the BioAlliance Pharma website at www.bioalliancepharma.com


About Topotarget
Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.


Disclaimer
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.